AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

Stock Information for AIM ImmunoTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AIM ImmunoTech Inc.

AI-Media Unveils LEXI Voice at NAB Show 2025 - Global Reach with Live AI-Powered Voice Translation
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
AI-Media Partners with AudioShake to Revolutionize Live Sports Audio and AI Voice Translation
LEXI Voice is Coming: AI-Media Releases Groundbreaking AI Voice Translation at NAB 2025
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.